Akums Drugs IPO: Price Band, Lot Size, Financials & Review
Akums Drugs IPO listed on BSE & NSE on Tue, 6 Aug 2024. The issue was subscribed 63.56x overall.
- Open Date
- 30 Jul 2024
- Close Date
- 1 Aug 2024
Last updated
- Price band
- ₹646 – ₹679
- Lot size
- 22 shares
- Min. investment
- ₹14,938
- Issue size
- ₹1,856.74 Cr
- Last GMP
- +₹43
- Subscribed
- 🔥 63.56x
Akums Drugs IPO details
Akums Drugs IPO is a ₹1,856.74 Cr book-building IPO on the Mainboard segment, listing on BSE & NSE. It combines a fresh issue of ₹680 Cr (36.62%) with an offer for sale of ₹1,176.74 Cr (63.38%) by existing shareholders. Only the fresh issue money goes to the company.
The issue was open from Tue, 30 Jul 2024 to Thu, 1 Aug 2024. Allotment was finalised on Fri, 2 Aug 2024, and the shares listed on BSE & NSE on Tue, 6 Aug 2024.
The price band is ₹646 to ₹679 per share and the lot size is 22 shares, so the minimum retail application is ₹14,938. Retail investors can apply for up to 13 lots (286 shares, ₹1,94,194).
MUFG Intime India Pvt Ltd is the registrar, and Citigroup Global Markets India Pvt.Ltd., Ambit Private Limited, Axis Capital Limited and ICICI Securities Limited are the book running lead managers.
Grey market premium (GMP)
Day-wise GMP →The last Akums Drugs IPO GMP before listing was +₹43 (+6.33% against the upper price band of ₹679), implying an estimated listing price of ₹722. Across 10 days of tracking, GMP ranged from +₹99 (03 Aug) to +₹211 (29 Jul).
| Last GMP | +₹43 |
|---|---|
| GMP vs upper band | +6.33% |
| Estimated listing price | ₹722 |
| Highest (29 Jul) | +₹211 |
| Lowest (03 Aug) | +₹99 |
Grey market trading is unofficial and unregulated. GMP is a sentiment indicator, not a guarantee of the listing price. See the Akums Drugs IPO day-wise GMP.
Subscription
Day-wise subscription →Akums Drugs IPO was subscribed 63.56x overall: QIB 90.09x, NII 42.21x and retail 21.30x.
| Category | Subscribed |
|---|---|
| QIB | 90.09x |
| NII | 42.21x |
| └ bNII (above ₹10 lakh) | 47.43x |
| └ sNII (₹2–10 lakh) | 31.78x |
| Retail | 21.30x |
| Employees | 4.27x |
| Total | 63.56x |
Final figures at the close of bidding on 1 Aug 2024. Category-wise bids, application-wise breakup and allotment chances are on the Akums Drugs IPO day-wise and category-wise subscription page.
Share reservation by category
| Category | Shares offered | Share of issue |
|---|---|---|
| Anchor Investors | 1,22,05,912 | 44.60% |
| Qualified Institutions | 81,37,276 | 29.73% |
| Non-Institutional | 40,68,637 | 14.87% |
| └ BNII | 27,12,425 | 9.91% |
| └ SNII | 13,56,212 | 4.96% |
| Retail Investors | 27,12,424 | 9.91% |
| Employees | 2,43,902 | 0.89% |
| Total | 2,73,68,151 | 100.00% |
Shares offered include the anchor investor portion, which is allotted a day before the issue opens. Subscription figures exclude anchors, so category sizes on the subscription page are smaller.
Akums Drugs IPO lot size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 22 | ₹14,938 |
| Retail (Max) | 13 | 286 | ₹1,94,194 |
| S-HNI (Min) | 14 | 308 | ₹2,09,132 |
| S-HNI (Max) | 66 | 1,452 | ₹9,85,908 |
| B-HNI (Min) | 67 | 1,474 | ₹10,00,846 |
Amounts at the upper end of the price band.
Issue structure and valuation
It combines a fresh issue of ₹680 Cr (36.62%) with an offer for sale of ₹1,176.74 Cr (63.38%) by existing shareholders. Only the fresh issue money goes to the company.
P/E is not meaningful here because earnings per share is zero or negative.
| EPS (pre-issue) Latest earnings per share before the issue | ₹0 |
|---|---|
| P/E (pre-issue) Upper price band ÷ pre-issue EPS | — |
| EPS (post-issue) EPS on the enlarged share capital | ₹0 |
| P/E (post-issue) Upper price band ÷ post-issue EPS | — |
| Promoter holding (pre-issue) | 84.94% |
| Promoter holding (post-issue) | 0.00% |
Akums Drugs and Pharmaceuticals Limited financials
Between 31 Mar 2023 and 31 Mar 2024, Income rose from ₹3,700.93 Cr to ₹4,212.21 Cr, and profit after tax fell from ₹97.82 Cr to ₹0.79 Cr. The PAT margin for 31 Mar 2024 was 0.02%.
| Period ended | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|
| Assets | 3,516.37 | 3,266.53 | 3,069.05 |
| Total Income | 4,212.21 | 3,700.93 | 3,694.52 |
| Profit After Tax | 0.79 | 97.82 | -250.87 |
| Net Worth | 709.50 | 717.19 | 621.98 |
| Reserve & Surplus | 861.01 | 868.70 | 787.79 |
| Total Borrowings | 491.56 | 536.97 | 357.95 |
₹ in crore, as stated in the prospectus.
Key performance indicators
| KPI | KPI as of March 31, 2024. |
|---|---|
| ROE % | 0.11 |
| ROCE % | 3.37 |
| Debt / Equity | 0.69 |
| RoNW % | -0.57 |
| PbW | 13.69 |
| Pat Margin % | 0.02 |
Objectives
The company intends to allocate the net proceeds from the offering to the following objectives.
| Sr | Objective |
|---|---|
| 1 | Repayment/ prepayment of indebtedness of the company and its Subsidiaries |
| 2 | Funding incremental working capital requirements of the company |
| 3 | Pursuing inorganic growth initiatives through acquisitions |
| 4 | General corporate purposes. |
About Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited, established in 2004, is a leading pharmaceutical contract development and manufacturing organization (CDMO) providing a comprehensive range of products and services in India and internationally.
The company offers end-to-end solutions for product development, manufacturing, research and development (R&D) of formulations, regulatory dossier preparation, and submission, along with other testing services. Akums is also involved in the manufacture and sale of branded drugs and active pharmaceutical ingredients (APIs).
As a CDMO, Akums produces a variety of dosage forms, including tablets, capsules, liquid medicines, vials, ampoules, blow-filled closures, topical preparations, eye drops, dry powder injections, and gummy bears. The company has commercialised 4,025 formulations in over 60 dosage forms and, in 2023, manufactured formulations for 26 of India's top 30 pharmaceutical companies by revenue. Akums operates 10 manufacturing units with a cumulative production capacity of 49.21 billion units annually as of September 30, 2023.
Promoters
- Sanjeev Jain
- Sandeep Jain
- Akums Master Trust
Contact details
Akums Drugs and Pharmaceuticals Limited
304, Mohan Place,
LSC Saraswati Vihar,
Delhi - 110 034
Phone: +91 11 6904 1000
Email: cs@akums.net
Website: http://www.akums.in
Akums Drugs IPO FAQs
- What is the Akums Drugs IPO price band?
- The Akums Drugs IPO price band is ₹646 to ₹679 per share.
- What is the Akums Drugs IPO lot size and minimum investment?
- The Akums Drugs IPO lot size is 22 shares. The minimum retail investment is ₹14,938 for one lot at the upper price band. Retail investors can apply for up to 13 lots (286 shares), costing ₹1,94,194.
- When was Akums Drugs IPO open for subscription?
- Akums Drugs IPO was open for subscription from Tue, 30 Jul 2024 to Thu, 1 Aug 2024.
- What is the Akums Drugs IPO subscription status?
- Akums Drugs IPO was subscribed 63.56x overall: QIB 90.09x, NII 42.21x and retail 21.30x. Day-wise and category-wise figures are on the subscription page.
- What was the Akums Drugs IPO GMP before listing?
- The last Akums Drugs IPO GMP before listing was +₹43 (+6.33% against the upper price band of ₹679), implying an estimated listing price of ₹722. Across 10 days of tracking, GMP ranged from +₹99 (03 Aug) to +₹211 (29 Jul). GMP is an unofficial grey market indicator and can change quickly.
- What is the Akums Drugs IPO allotment date?
- The Akums Drugs IPO basis of allotment was finalised on Fri, 2 Aug 2024. You can check your allotment status on the MUFG Intime India Pvt Ltd website.
- What is the Akums Drugs IPO listing date?
- Akums Drugs IPO listed on BSE & NSE on Tue, 6 Aug 2024.
- Is the Akums Drugs IPO a fresh issue or an offer for sale?
- It combines a fresh issue of ₹680 Cr (36.62%) with an offer for sale of ₹1,176.74 Cr (63.38%) by existing shareholders. Only the fresh issue money goes to the company.
- Who are the registrar and lead managers of the Akums Drugs IPO?
- The registrar for the Akums Drugs IPO is MUFG Intime India Pvt Ltd, and the book running lead managers are Citigroup Global Markets India Pvt.Ltd., Ambit Private Limited, Axis Capital Limited and ICICI Securities Limited.
Data is compiled from the prospectus, stock exchanges and market sources and is for information only. It is not investment advice; read the RHP before applying.